Peptides9 min read
Thymosin alpha-1 is not a generic immune booster
Immune-cell changes are not the same as clinical benefit. Read thymosin alpha-1 evidence through the actual illness, treatment and outcome being studied.
Read articleBlog
Research, explained. Explore peptides, supplements and hormone health with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides9 min read
Why elamipretide's blinded trial and extension tell different stories
TAZPOWER's randomized and open-label periods used different comparisons. Understanding the endpoints explains the findings and Forzinity's accelerated approval.
Read article
Peptides7 min read
PT-141 nausea: weighing benefit against tolerability
Nausea can determine whether bremelanotide is worth continuing. Explore trial rates, timing, stopping treatment, and the tested ondansetron regimen.
Read article
Peptides9 min read
PEG-MGF and anti-doping: why the exact category matters
MGFs are explicitly listed under WADA S2.3. Understand the current rules, future list dates and why detection research does not prove clinical benefits.
Read article
Peptides8 min read
The 2026 TB-500 compounding debate: which substance was reviewed?
The July FDA materials concerned specific forms of a seven-amino-acid fragment. Understand the identity, evidence and regulatory questions separately.
Read article
Peptides9 min read
Can a sleep tracker validate a DSIP experiment?
A tracker can describe sleep trends, but measurement accuracy and proof that DSIP caused a change are separate questions.
Read article
Peptides9 min read
Why a host-defense peptide is not automatically safe to inject
Natural origin does not establish injection safety. Read the human LL-37 exposure record, product-quality questions and the limits of topical evidence.
Read article
Peptides8 min read
GHRP-2 in sport: the rules do not depend on whether it works for you
GHRP-2 is named on the 2026 and published 2027 WADA lists. Clinical use, sporting permission and laboratory detection each answer a different question.
Read article
Peptides9 min read
Weight-loss peptides: why lean mass and muscle are different claims
What STEP 1 and other human studies actually measured—and why lean mass, skeletal muscle, body-weight percentages and strength are different outcomes.
Read article
Peptides9 min read
Intranasal oxytocin: delivery does not settle clinical benefit
Blood, cerebrospinal fluid, brain tissue, and patient outcomes answer different questions about nasal oxytocin.
Read article
Peptides9 min read
Thymosin alpha-1 and vaccine response: does it mean fewer infections?
Antibody findings in vaccine trials are useful, but they do not establish general infection prevention. Explore the human studies and their practical limits.
Read article
Peptides9 min read
Why small ARA-290 trials leave large safety questions
What ARA-290 trials monitored, which serious events were reported, and why short studies cannot settle uncommon or longer-term risks.
Read article133–144 of 321 articles